Eosinophil counts can be a predictive marker of immune checkpoint inhibitor-induced secondary adrenal insufficiency: a retrospective cohort study.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
25 01 2022
25 01 2022
Historique:
received:
03
10
2021
accepted:
11
01
2022
entrez:
26
1
2022
pubmed:
27
1
2022
medline:
5
3
2022
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICIs) treatment can result in endocrine immune-related adverse events (irAEs), including pituitary dysfunction. Quick diagnosis of secondary adrenal insufficiency (AI) is challenging because no universal definition of ICI-induced secondary AI has been agreed. The aim of this study was to clarify the clinical features of ICI-induced secondary AI that can be used for screening in standard clinical practice. This retrospective study was performed using the medical records of patients who received ICIs at Hirosaki University Hospital between 1 September 2014 and 31 January 2021. Longitudinal clinical data of patients who developed AI were analyzed and compared with the data of thyroid irAEs. Regression analysis showed a significant correlation between ICI-induced secondary AI and absolute or relative eosinophil counts at pre-onset of AI, as well as differences or rate of increase in eosinophil counts at baseline and at pre-onset. Absolute eosinophil counts > 198.36/µL or relative eosinophil counts > 5.6% at pre-onset, and a difference of 65.25/µL or a rate of eosinophil count increase of 1.97 between the baseline and at pre-onset showed the best sensitivity and specificity. This is the first report to demonstrate that eosinophil counts can be a predictor of ICI-induced secondary AI.
Identifiants
pubmed: 35079086
doi: 10.1038/s41598-022-05400-x
pii: 10.1038/s41598-022-05400-x
pmc: PMC8789805
doi:
Substances chimiques
Biomarkers
0
Immune Checkpoint Inhibitors
0
C-Reactive Protein
9007-41-4
Sodium
9NEZ333N27
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1294Informations de copyright
© 2022. The Author(s).
Références
Am J Med Sci. 2010 Jun;339(6):525-31
pubmed: 20400889
JAMA Oncol. 2018 Feb 1;4(2):173-182
pubmed: 28973656
Endocrinol Diabetes Metab Case Rep. 2019 Oct 12;2019:
pubmed: 31610523
Medicine (Baltimore). 2017 Nov;96(45):e8463
pubmed: 29137033
Anticancer Res. 2017 Aug;37(8):4229-4232
pubmed: 28739711
Sci Rep. 2020 Aug 11;10(1):13546
pubmed: 32782279
Future Sci OA. 2020 Aug 03;6(10):FSO608
pubmed: 33312694
Jpn J Clin Oncol. 2019 May 1;49(5):431-437
pubmed: 30753621
Endocr J. 2019 Oct 28;66(10):937-941
pubmed: 31217401
Sci Rep. 2015 May 22;5:10508
pubmed: 26001129
Eur J Cancer. 2017 Aug;81:135-137
pubmed: 28624693
Endocr J. 2016 Sep 30;63(9):765-784
pubmed: 27350721
Cancer Immunol Immunother. 2021 Dec;70(12):3669-3677
pubmed: 33977343
J Clin Endocrinol Metab. 2016 Feb;101(2):364-89
pubmed: 26760044
Pathobiology. 2019;86(1):39-52
pubmed: 29961056
Oncotarget. 2017 Dec 14;8(69):114268-114280
pubmed: 29371985
Urol Oncol. 2014 Jan;32(1):50.e1-8
pubmed: 24239465
Lancet. 1999 May 15;353(9165):1675-6
pubmed: 10335792
Clin Endocrinol (Oxf). 2005 Oct;63(4):366-74
pubmed: 16181228
Endocr Connect. 2017 Nov;6(8):935-942
pubmed: 29089364
Endocr Connect. 2020 Oct;9(10):R207-R228
pubmed: 33064663
Proc Natl Acad Sci U S A. 2019 Oct 29;116(44):22246-22251
pubmed: 31611368
Eur J Cancer. 2016 Feb;54:139-148
pubmed: 26765102
Clin Endocrinol (Oxf). 2019 Dec;91(6):786-792
pubmed: 31468541
Cancer Immunol Immunother. 2019 May;68(5):823-833
pubmed: 30302498
Cancer Causes Control. 2015 Nov;26(11):1661-70
pubmed: 26376895
Oncoimmunology. 2020 Apr 7;9(1):1722022
pubmed: 32313716
Eur J Endocrinol. 2019 Sep;181(3):211-219
pubmed: 31176301
J Am Med Assoc. 1948 Jul 17;137(12):1005-9
pubmed: 18871855
Am J Med. 2016 Mar;129(3):339.e1-9
pubmed: 26363354
Eur J Cancer. 2020 May;130:198-203
pubmed: 32229416
Endocrine. 2017 Nov;58(2):312-319
pubmed: 28913704
Endocr J. 2017 Feb 27;64(2):235-236
pubmed: 28070057
J Immunother Cancer. 2020 Jul;8(2):
pubmed: 32606047
Clin Endocrinol (Oxf). 2021 Feb;94(2):258-268
pubmed: 33037658
Cancer. 2018 Mar 15;124(6):1111-1121
pubmed: 29313945